Q-omics provides the consensus-scored IVL profile across patient tissues and cancer cell-line models. IVL expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, IVL is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, IVL protein abundance shows 14,673 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, THCA, and HNSC as cancer lineages where IVL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IVL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IVL survival associations across molecular data types. IVL RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IVL RNA expression–survival associations across cancer types. High IVL expression shows unfavorable associations in MESO, BRCA, KIRP, SKCM and DLBC, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for IVL RNA expression.
This table summarizes IVL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IVL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IVL shows lower tumor expression in KICH and higher tumor expression in THCA, LUSC, LUAD, BRCA and UCEC. The THCA box plot shows higher IVL RNA expression in tumor versus normal tissue (log2 FC = +2.439, t-test p < 0.001).
This table shows molecular features associated with IVL in patient tissues and cancer cell lines. In patient samples, IVL shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, IVL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
